Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
Here’s What Happened
Novo Nordisk’s semaglutide composition-of-matter patent expires in the United States in March 2027 (extending to September 2027 with pediatric exclusivity). With 38.7 billion dollars in 2025 revenue at stake, semaglutide is the most valuable patent expiry in pharmaceutical history. At least eight companiesare developing biosimilar versions, but the barriers to entry — five hundred million dollars capital requirements, 40+ process patents extending to 2034, and unprecedented manufacturing complexity — will limit the field to a handful of viable competitors. Here is the competitive landscape as of mid-2026.
The Contenders
Sandoz | Phase I/III | In-house (Austria) | 2029 | Biosimilar market leader; European strength.
Hybio/Sinopep | Preclinical/Phase I | In-house (China) | 2029–2030 | Lowest manufacturing cost.
The competitive landscape reveals a tight race among the first three entrants, with Biocon holding a slight lead based on biosimilar experience and integrated manufacturing. But, the timeline is highly sensitive to litigation: Novo Nordisk has filed patent infringement suits against Biocon and Viatris, alleging that their manufacturing processes infringe process patents extending to 2034. If the courts side with Novo Nordisk, biosimilar entry could be delayed until 2032–2034.
Pricing Implications
Biosimilar pricing for peptide drugs does not follow the small-molecule generic pattern of 80–ninety percent discounts. The capital intensity, manufacturing complexity, and regulatory requirements for peptide biosimilars create a natural oligopoly: when there are fewer than 5 competitors, price discounts typically stabilize at 20–forty percent. The first biosimilar semaglutide is likely to launch at a 25–thirty-five percent discount to the reference product, with prices declining to a 40–sixty percent discount as additional entrants join. This is consistent with the pricing dynamics observed for other peptide biosimilars (glatiramer acetate, teriparatide) and fundamentally different from small-molecule generic erosion.
Expert Insight: The ANDA vs. 505(b)(2) Question
The regulatory pathway for semaglutide biosimilars is itself contested. Biocon and Viatris are pursuing 351(k) biosimilar applications under the BPCIA, which requires clinical immunogenicity data but provides 12 months of first-mover exclusivity for the first interchangeable designation. Sandoz appears to be pursuing a 505(b)(2) NDA, which relies in part on Novo Nordisk’s clinical data but requires less extensive analytical similarity demonstration. The choice of pathway has enormous commercial implications: a 351(k) interchangeable designation allows pharmacy-level substitution (the holy grail of biosimilar uptake), while a 505(b)(2) NDA does not.
What experienced regulatory strategists know: The FDA has never designated a peptide as interchangeable under the BPCIA. The analytical complexity of demonstrating “no clinically meaningful differences” for a 31-residue lipidated peptide — where each batch contains dozens of structurally related impurities — is unprecedented. The first company to achieve interchangeable designation for a peptide biosimilar will set a precedent that shapes the regulatory pathway for the entire class.
Further Reading
[Natural sign-off — one sentence summary of why this matters.]
Last reviewed: June 2026. Peptide Proof Editorial Team.
